Motivating Patients and Maintaining Rigor in Cardiovascular Clinical Trials
Cardiovascular research can feel like a “numbers game” from design and recruitment to analysis. Worldwide brings the experience, decisiveness and tailored solutions your program needs.
Dedicated cardiovascular teams, 30 years and counting
Worldwide wins the numbers game. We have more than three decades of experience in cardiovascular research, a presence in more than 60 countries, and extensive global trial experience in all phases of research—even involving more than 26,000 patients in a single trial. Yet every single program receives the attention and care of a dedicated team, enabling us to act quickly and effectively in close collaboration with key industry partners.
ETERI TSETSKHLADZE, MD, PHD, FESC, FACC
VICE PRESIDENT, GENERAL MEDICINE MEDICAL LEAD, MEDICAL AFFAIRS
As a clinician, investigator, and educator, Dr. Tsetskhladze embodies Worldwide’s commitment to supporting improved health care options. Since joining the Worldwide Clinical Trials team in 2004, she has supported more than 70 studies in her capacity as medical director and therapeutic advisor. She combines scientific and clinical rigor with an intimate understanding of the patient’s experience, and is adept at translating medical and scientific findings into accessible data to serve commercial and regulatory objectives. Dr. Tsetskhladze is a fellow of the American College of Cardiology (ACC) and the European Society of Cardiology (ESC), while also serving on a number of therapeutic working groups. She is credited with more than 50 publications.
SENIOR DIRECTOR, PROJECT MANAGEMENT
Lucy Bennett, Senior Director of Project Management for the UK, has been a member of the Cardiometabolic group at Worldwide Clinical Trials for almost three decades. Her experience with data management, site management and monitoring, and project management brings an intimate understanding of sponsors’ needs. She currently provides global oversight of internal and external teams and vendors, with responsibilities bridging the full life span of the clinical trial, from start-up through maintenance and closure.
NANCY NEWARK, RN
Executive Director, Project Management, Cardiovascular
Nancy combines keen attention to clinical rigor with a capacity to oversee global multi-center clinical trials. As franchise lead within Worldwide’s cardiovascular therapeutic area, she provides operational oversight and leadership for our cardiovascular clinical trials, with responsibility for strategic development, regulatory compliance, site management, and clinical monitoring. After more than a decade working as a critical care transport nurse, she provided senior operational leadership for global multi-center clinical trials and registries, including direct responsibility for regulatory compliance, project management, and more at the Duke Clinical Research Institute (DCRI) for 14 years. She has been with Worldwide since 2010.
Innovative Recruitment and Retention Strategies for Phase III Rare Cardiovascular Disease Study
See how Worldwide’s expertise in cardio patient recruitment strategies helped address three concerns during this phase III PAH clinical study.Learn More
Pulmonary Arterial Hypertension Clinical Trial
Fact sheet on pulmonary arterial hypertension (PAH) trials.Learn More
Flawlessly Execute Your Cardiovascular Clinical Trials with Worldwide’s Support
Worldwide has deep experience in ensuring cardiovascular trials stay on time and on budget. Learn more with this fact sheet.Learn More
Bringing a 12,000-patient Cardiovascular Outcome Trial to Database Lock
How did Worldwide Clinical Trials execute a 12,000-patient mega trial and meet recruitment and study milestones ahead of schedule? Read this case study to find out.Learn More
Our experience executing large cardiovascular trials has resulted in irreplaceable expertise: a solid understanding of the events, treatment, and outcomes of interest. These studies require event adjudication and close collaboration with Clinical Events Committees (CECs).
Smart screening and high compliance rates reduce enrollment costs. Paired with thoughtful statistical analysis plans and early leading signals for rapid identification of struggling products, we offer shorter trials for patients and faster decision-making guidance for sponsors.
Worldwide can do more than screen patients for inclusion and exclusion criteria. Using emerging predictive analytics technology, we identify the study subjects most likely to comply with the protocol and stay the course of the trial.
Worldwide minimizes attrition and improves statistical validity by anticipating the pain points most likely to cause attrition. We then proactively work to alleviate those concerns, honoring patients’ time and commitment through compressed timelines and reduced study burden.
Cultivating cardiovascular success stories one patient—and study—at a time
Cardiovascular trials often require teamwide dedication to a broad scope and a patient, detail-oriented operational approach. At Worldwide, we believe each study relies on the commitment of the individuals involved. Find out how this comes through in everything we do.
- Acute Coronary Syndrome (ACS)
- Atrial Fibrillation
- Cardiac Arrhythmias
- Coronary Artery Disease (CAD)
- Heart Failure
- Ischemic Heart Disease
- Myocardial Infarction
- Pulmonary Arterial Hypertension (PAH)
- Stroke/Cerebrovascular Disease – Prevention
Our Dedicated Team
Senior Vice President, Project Management, Cardiovascular, Endocrine & Metabolic and Real-World Evidence
Executive Director, Project Management, Cardiovascular
Vice President, General Medicine Medical Lead, Medical Affairs
Vice President Project Management, Cardiovascular
Executive Director, Scientific Solutions, Cardiovascular, Endocrine & Metabolic
Global Head of Regulatory Strategy
Senior Director, Project Management
Senior Medical Director, Medical Affairs, Cardiovascular, Endocrine & Metabolic